Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805
Journal of the National Comprehensive Cancer Network · 2023-07 · 21 (7) · 725-731.e1
DOI: 10.6004/jnccn.2023.7018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023-07. Verfasst von Wendy J Bottinor und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia. Hauptthemen laut MEDLINE: Hypertension, Cardiovascular Diseases, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality among adolescents and young adults (AYAs) diagnosed with cancer. The aim of this study was to assess the incidence and predictors of left ventricular systolic dysfunction (LVSD) and hypertension among AYAs receiving VEGF inhibition compared with non-AYAs.
Methods
This retrospective analysis used data from the ASSURE trial (ClinicalTrials.gov identifier: NCT00326898 ), in which participants with nonmetastatic, high-risk, renal cell cancer were randomized to sunitinib, sorafenib, or placebo. The incidence of LVSD (left ventricular ejection fraction decrease >15%) and hypertension (blood pressure ≥140/90 mm Hg) were compared using nonparametric tests. Multivariable logistic regression examined the association between AYA status, LVSD, and hypertension while adjusting for clinical factors.
Results
AYAs represented 7% (103/1,572) of the population. Over a study treatment period of 54 weeks, the incidence of LVSD was not significantly different among AYAs (3%; 95% CI, 0.6%–8.3%) versus non-AYAs (2%; 95% CI, 1.2%–2.7%). The incidence of hypertension was significantly lower among AYAs (18%; 95% CI, 7.5%–33.5%) compared with non-AYAs (46%; 95% CI, 41.9%–50.4%) in the placebo arm. In the sunitinib and sorafenib groups, the incidence of hypertension for AYAs compared with non-AYAs was 29% (95% CI, 15.1%–47.5%) versus 47% (95% CI, 42.3%–51.7%), and 54% (95% CI, 33.9%–72.5%) versus 63% (95% CI, 58.6%–67.7%), respectively. AYA status (odds ratio, 0.48; 95% CI, 0.31–0.75) and female sex (odds ratio, 0.74; 95% CI, 0.59–0.92) were each associated with a lower risk of hypertension.
Conclusions
LVSD and hypertension were prevalent among AYAs. CVD among AYAs is only partially explained by cancer therapy. Understanding CVD risk among AYA cancer survivors is important for promoting cardiovascular health in this growing population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Internal Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond, Virginia.
- Department of Data Science/ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Division of Medical Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
- Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington, Kentucky.
- School of Medicine, Hofstra University, New York, New York.
- Department of Medical Social Sciences, Northwestern Medicine, Chicago, Illinois.
Förderung
- NCI NIH HHS
- NCATS NIH HHS
Zitieren
APA
Bottinor, W. J., Flamand, Y., Haas, N. B., ONeill, A. M., DiPaola, R. S., Subramanian, P., Cella, D., Hundley, W. G., Wagner, L. I., Salsman, J. M., & Ky, B. (2023). Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805. Journal of the National Comprehensive Cancer Network, 21(7), 725-731.e1. https://doi.org/10.6004/jnccn.2023.7018
Vancouver
Bottinor WJ, Flamand Y, Haas NB, ONeill AM, DiPaola RS, Subramanian P, et al. Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805. Journal of the National Comprehensive Cancer Network. 2023;21(7):725-731.e1. doi:10.6004/jnccn.2023.7018
BibTeX
@article{Bottinor2023,
author = {Bottinor, Wendy J and Flamand, Yael and Haas, Naomi B and ONeill, Anne M and DiPaola, Robert S and Subramanian, Pearl and Cella, David and Hundley, W Gregory and Wagner, Lynne I and Salsman, John M and Ky, Bonnie},
title = {Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2023},
volume = {21},
number = {7},
pages = {725--731.e1},
doi = {10.6004/jnccn.2023.7018}
}
EUVIMED